Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice
Suzanne M. Scheaffer(Washington University in St. Louis), Diana Lee(Moderna Therapeutics (United States)), Bradley Whitener(Washington University in St. Louis), Baoling Ying(Washington University in St. Louis), Kaichun Wu(Moderna Therapeutics (United States)), Chieh-Yu Liang(Washington University in St. Louis), Hardik Jani(Moderna Therapeutics (United States)), Philippa Martin(Moderna Therapeutics (United States)), Nicholas J. Amato(Moderna Therapeutics (United States)), Laura E. Avena(Moderna Therapeutics (United States)), Daniela Montes Berrueta(Moderna Therapeutics (United States)), Stephen D. Schmidt(National Institute of Allergy and Infectious Diseases), Sijy O’Dell(National Institute of Allergy and Infectious Diseases), Arshan Nasir(Moderna Therapeutics (United States)), Gwo‐Yu Chuang(Moderna Therapeutics (United States)), Guillaume B. E. Stewart-Jones(Moderna Therapeutics (United States)), Richard A. Koup(National Institute of Allergy and Infectious Diseases), Nicole A. Doria‐Rose(National Institute of Allergy and Infectious Diseases), Andrea Carfı́(Moderna Therapeutics (United States)), Sayda M. Elbashir(Moderna Therapeutics (United States)), Larissa B. Thackray(Washington University in St. Louis), Darin K. Edwards(Moderna Therapeutics (United States)), Michael Diamond(Washington University in St. Louis)
Cited by 182Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis